PPA-904
目录号 : GC32027
PPA-904是一种特异性的吩噻嗪光敏剂，用于光动力疗法。
Cas No.:30189-85-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Mice: 106 metacyclic parasites in 20 mL of PBS are inoculated intradermally into the ears of 6- to 8-week-old BALB/c female mice. A PPA904 cream is applied topically onto the lesion under dark conditions. The areas in the right ear are then irradiated with LC-122A, non-coherent light source equipped with a broadband optical filter, which is inserted into the light delivery system. The filter peaks at 665 nm and has a half-band width of 30 nm. A fluence of 50 J/cm2 (50 mW/cm2) is delivered to the lesion on the right ear, while the left ear (and left ears of the other mice in this group) serves as the drug only group. The ears from mice with no procedure serve as the infected nontreated group. Mice are sacrificed 5 days after photodynamic therapy. Parasite loads in the ears are determined[1]. |
References: [1]. Akilov OE,et al. Optimization of topical photodynamic therapy with 3,7-bis(di-n-butylamino)phenothiazin-5-ium bromide for cutaneous leishmaniasis. Lasers Surg Med. 2009 Jul;41(5):358-65. | |
PPA-904 is a specific phenothiazine photosensitizer used in photodynamic therapy.
Topical PPA904 photodynamic therapy is a promising treatment for cutaneous leishmaniasis. The best curative PPA904-photodynamic therapy regimen is achieved under the conditions of a longer duration of topical application time (90 minutes) and several (three) consecutive treatments with 4-day intervals between treatments[1]. PPA904-PDT can provide an immunomodulating, dose-dependent efflux on IL-12p70 production. This mechanism could be responsible for promoting a more rapid healing in PPA904-PDT treated mice[2]. Treatment of PPA904 is well tolerated with no reports of pain or other safety issues. PPA904 treated subjects show a reduction in bacterial load immediately post-treatment. After 3 months, 50% (four of eight) of subjects with actively treated chronic leg ulcer show complete healing, compared with 12% (one of eight) of subjects on placebo[3].
[1]. Akilov OE,et al. Optimization of topical photodynamic therapy with 3,7-bis(di-n-butylamino)phenothiazin-5-ium bromide for cutaneous leishmaniasis. Lasers Surg Med. 2009 Jul;41(5):358-65. [2]. Akilov OE, et al. Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochem Photobiol Sci. 2007 Oct;6(10):1067-75. [3]. Morley S, et al. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol. 2013 Mar;168(3):617-24.
| Cas No. | 30189-85-6 | SDF | |
| Canonical SMILES | CCCCN(C1=CC2=[S+]C3=C(C=CC(N(CCCC)CCCC)=C3)N=C2C=C1)CCCC.[Br-] | ||
| 分子式 | C28H42BrN3S | 分子量 | 532.62 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8775 mL | 9.3876 mL | 18.7751 mL |
| 5 mM | 0.3755 mL | 1.8775 mL | 3.755 mL |
| 10 mM | 0.1878 mL | 0.9388 mL | 1.8775 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。